S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 (2014/12/12)|
|ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis (2014/12/4)|
|ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140, an Orally Administered CCR2 Inhibitor (2014/12/11)|
|ChemoCentryx to Present at the 33rd Annual J.P. Morgan Healthcare Conference (2015/1/6)|
|ChemoCentryx to Present at the Cowen and Company 35th Annual Health Care Conference (2015/2/17)|
|ChemoCentryx to Hold Fourth Quarter 2014 Financial Results Conference Call on Thursday, March 12, 2015 (2015/2/26)|
Click above to view more mutual fund data and stats for ccxi - Chemocentryx Inc.